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Abstract
Background: With antidepressants (ADs) having minimal therapeutic effects during the initial weeks of treatment,
benzodiazepines (BZDs) are concomitantly used to alleviate depressive symptoms of insomnia or anxiety. However,
with mortality risks associated with this concomitant use yet to be examined, it remains unclear as to whether this
concomitant therapy offers any benefits in treating depression.
Methods: We conducted a population-based cohort study using South Korea’s nationwide healthcare database
from 2002 to 2017. Of 2.6 million patients with depression, we identified 612,729 patients with incident depression
and newly prescribed ADs or BZDs, by excluding those with a record of diagnosis or prescription within the 2 years
prior to their incident diagnosis. We classified our study cohort into two discrete groups depending on the type of
AD treatment received within 6 months of incident diagnosis—AD monotherapy and AD plus BZD (AD+BZD)
therapy. We matched our study cohort in a 1:1 ratio using propensity scores to balance baseline characteristics and
obtain comparability among groups. The primary outcome was all-cause mortality, and patients were followed until
the earliest of outcome occurrence or end of the study period. We conducted multivariable Cox proportional
hazards regression analysis to estimate adjusted hazards ratios (HRs) with 95% confidence intervals (CIs) for the risk
of mortality associated with AD+BZD therapy versus AD monotherapy.
Results: The propensity score-matched cohort had 519,780 patients with 259,890 patients in each group, where all
baseline characteristics were well-balanced between the two groups. Compared to AD monotherapy, AD+BZD
therapy was associated with an increased risk of all-cause mortality (adjusted HR, 1.04; 95% CI, 1.02 to 1.06).
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Conclusions: Concomitantly initiating BZDs with ADs was associated with a moderately increased risk of mortality.
Clinicians should therefore exercise caution when deciding to co-prescribe BZDs with ADs in treating depression, as
associated risks were observed.
Keywords: Antidepressants, Benzodiazepines, Concomitant therapy, Depression
Background
Depression is a common psychiatric illness that affects >
300 million patients worldwide [1]. Accordingly, the
utilization of antidepressants (ADs) has increased over time
as well [2–5]. With ADs having minimal therapeutic effects
during the initial weeks of administration [6], benzodiaze-
pines (BZDs) are often additionally administered to manage
anxiety or insomnia in patients with depression [7, 8]; one
in 10 patients who initiated ADs concomitantly initiated
BZDs in the USA [9]. However, BZDs are sometimes con-
tinued for longer periods than intended in real-world clin-
ical practice, possibly owing to their dependency—one
study found that approximately 12% of patients who re-
ceived concomitant BZD and AD therapy (AD+BZD) con-
tinued long-term BZD use [9]. Despite such prevalence,
uncertainties remain regarding the safety of AD+BZD ther-
apy for the treatment of patients with depression.
To our knowledge, no previous study, observational or
randomized controlled trial, has assessed the risk of mortal-
ity associated with AD+BZD therapy, as compared with
AD therapy alone, among depressed patients. With no con-
sensus on the potential benefits or harms of BZDs when
used with ADs, clinical guidelines [10, 11] have expressed
concerns regarding prolonged BZD use, especially as sev-
eral studies reported an increased risk of mortality associ-
ated with it [12, 13]. Moreover, a meta-analysis of
randomized trials found that adults with depression who
received AD+BZD therapy reported more adverse events
than those receiving ADs alone [7]. However, as random-
ized trials are generally more focused on assessing the med-
ication’s efficacy, observational studies are needed to make
a formal assessment regarding mortality. Meanwhile, one
meta-analysis found that AD+BZD therapy could poten-
tially improve depression severity and remission compared
to AD therapy alone [14]. To date, the benefit or harm as-
sociated with AD+BZD therapy remains uncertain with
limited real-world evidence available on its use.
Therefore, this nationwide cohort study aimed to inves-
tigate the risk of mortality associated with concomitant
AD+BZD therapy when compared to AD monotherapy
among patients with incident depression.
Methods
Data source
We used the National Health Insurance Service-National
Health Insurance Database (NHIS-NHID) of South
Korea [15], which contains health insurance claims data
for the entire Korean population of 50 million inhabitants
collected between 1 January 2002 and 31 December 2017.
The NHIS-NHID is comprised of anonymized patient
identifier and corresponding information on associated
sociodemographic characteristics (age, sex, health insur-
ance type, and income level), healthcare utilization history,
diagnostic codes based on the International Classification
of Diseases 10th Revision (ICD-10), and drug prescription
information (national drug codes [NDC], days’ supply,
dosage, and administration route). The NDCs are based
on the drug’s active ingredient and mapped to the World
Health Organization’s Anatomical Therapeutic Chemical
classification codes. Moreover, the date of death was
linked to the national vital statistics maintained by Statis-
tics Korea.
Study population
We identified patients with either a primary or second-
ary recorded diagnosis of incident depression (ICD-10:
F32, F33, F34.1) from both inpatient and outpatient set-
tings between 1 January 2004 and 31 December 2017
(Fig. 1). Cohort entry was defined as the date of incident
diagnosis with depression. The following patients were
excluded from our study: (1) those diagnosed with de-
pression (ICD-10: F32, F33), bipolar disorders (F31),
manic episodes (F30), or persistent mood disorders
(F34) within 2 years prior to cohort entry, to restrict the
analysis to incident patients with depression; (2) those
prescribed any ADs or BZDs within 2 years prior to co-
hort entry to restrict to new users of ADs or BZDs; (3)
those aged < 18 years at cohort entry as depression is un-
likely to be prevalent and because AD or BZD use is not
advised in this age group; and (4) missing demographic
information.
Exposure definition
We used prescription records of ADs and BZDs from
both inpatient and outpatient settings to ascertain ex-
posure, where an intention-to-treat approach was used
to define follow-up (Additional file 1: Table S1). Pre-
scriptions of ADs or BZDs within 6 months after cohort
entry were eligible. Exposure was classified into two
groups and their corresponding index dates were defined
as follows: (1) AD monotherapy, date when one class of
AD was prescribed in a single prescription; (2) AD+BZD
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therapy, date when ADs were prescribed together
with BZDs in a single prescription on the same day
(Additional file 2: Fig. S1 and Additional file 3: Fig. S2).
Outcome definition
Time to all-cause mortality was our primary outcome of
interest. Our secondary outcomes were the time to inci-
dent diagnosis with suicide attempt/self-harm (from both
inpatient and outpatient settings) and time to all-cause
hospitalization, defined as a visit to a medical institution
resulting in admission. Follow-up began on the index date
and ended on the earliest of the outcome occurrence, or
end of the study period (31 December 2017).
Potential confounders
Age, sex, health insurance type, residential district, and
income level were assessed at cohort entry. Furthermore,
comorbidities (anxiety, cancer, cerebrovascular disease,
chronic kidney disease, chronic obstructive pulmonary
disease, dementia, diabetes mellitus, epilepsy, fractures,
hypertension, hyperlipidemia, insomnia, ischemic heart
disease, osteoarthritis, Parkinson’s disease, rheumatoid
arthritis, and substance abuse) and history of medication
use (angiotensin-converting-enzyme inhibitors, angio-
tensin II receptor blockers, anticholinergics, antiplatelets
and anticoagulants, antipsychotics, anticonvulsants, digoxin,
non-insulin glucose-lowering agents, anti-inflammatory an-
algesics, beta-blockers, calcium channel blockers, insulin,
lipid-lowering agents, narcotic analgesics, nonsteroidal anti-
inflammatory drugs, other anxiolytics, and thiazide di-
uretics) were assessed within the year before cohort entry.
Comorbidities were defined using ICD-10 codes and use of
medications was defined using NDCs (Additional file 1:
Table S1). The Charlson comorbidity index (CCI) score
was also estimated to determine the overall comorbidity
burden [16].
Fig. 1 Study cohort flowchart. *Study outcomes comprised all-cause mortality, suicide attempt/self-harm, or all-cause hospitalization. Note: AD,
antidepressants; BZD, benzodiazepines; NHIS-NHID, National Health Insurance Service-National Health Insurance Database
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To obtain comparability between treatment groups, we
conducted propensity score (PS) matching, where the PS
of receiving AD therapy was estimated using multivari-
able logistic regression. Upon conducting chi-square
tests to determine statistical significance between each
confounder and all-cause mortality, only confounders
that had p value < 0.2 were included as independent var-
iables into the multivariable logistic regression model
(history of other anxiolytic use was not included in the
model) [17]; age and sex were always included regardless
to their p value. Matching based on PS was done in a 1:1
ratio for the two groups using the Greedy 5→1 digit
matching macro [18, 19], where the c statistic (0.6–0.8)
was used to assess model discrimination [20].
Statistical analyses
The baseline characteristics of our study subjects are
represented as counts (proportions) and means (stand-
ard deviations) for categorical and continuous variables,
respectively. We estimated the absolute standardized dif-
ference (aSD) to determine imbalances between groups
(aSD > 0.1 indicated an important imbalance) [21].
We first aimed to examine the risk of study outcomes
by calculating the incidence of study outcomes per 1000
person-years and estimating the absolute risk and risk
differences with 95% confidence intervals (CIs). Adjusted
hazard ratios (HRs) with 95% CIs for study outcomes as-
sociated with AD+BZD therapy versus AD monotherapy
were estimated using multivariable Cox proportional
hazards regression, adjusted for all potential con-
founders. We tested for the proportional hazards as-
sumption by using the Schoenfeld residuals and found a
p value of 0.0003. As the proportional hazards assump-
tion was violated and, thus, indicated non-proportional
hazards, we stratified into different, non-overlapping
time periods in 1-year intervals to utilize all available
follow-up. Moreover, we plotted the cumulative inci-
dence for the risk of study outcomes associated with the
type of AD therapy received.
Subgroup analyses
Stratification was based on age (< 65 years versus ≥ 65
years), and sex, where a single model with interaction
terms, was used to observe whether the association be-
tween exposure and outcome differed significantly
among subgroups. Moreover, among AD+BZD recipi-
ents, we stratified on the type of BZD received (short-
acting versus long-acting; patients who received both
BZD types with antidepressants were excluded in this
subgroup analysis) and patients who discontinued BZDs,
defined as those who did not use benzodiazepines con-
tinuously for 6 months (180 days) after the index date;
this definition was previously used by several studies and
is considered a common definition [9, 22]. Benzodiazepine
treatment length was defined using a 30-day grace period
that was added to the days’ supply to allow for gaps in
between prescriptions.
Sensitivity analyses
First, we varied the definition of concomitant therapy to
at least one prescription of BZD within 2 weeks of the
first AD prescription (Additional file 4: Fig. S3). Second,
exposure was ascertained using an as-treated approach,
where patients were censored when they have either dis-
continued treatment (defined as when no new AD or
BZD prescription was given within 30 days of the end of
the previous prescription [23]) or added BZDs through-
out follow-up among AD monotherapy recipients. Third,
we applied two other PS methods of inverse probability
of treatment weighting and model adjustment [19, 24].
Lastly, we estimated the E-value to assess the potential
impact of unmeasured confounders on our study find-
ings [25], where in brief, a large E-value would imply
that large unmeasured confounding would be needed to
explain the observed association. All analyses were per-
formed using the SAS Enterprise Guide program pro-
vided by the NHIS (Release 9.71, SAS Institute Inc.,
Cary, NC, USA).
Results
Of 2,642,774 patients with depression, we identified 612,
729 patients to be included in our study cohort. Among
the 519,780 patients in our 1:1 PS-matched cohort, 259,
890 received AD monotherapy and AD+BZD therapy,
respectively (c statistics: 0.585 for AD monotherapy ver-
sus AD+BZD therapy) (Fig. 1). Of AD+BZD therapy re-
cipients prior to PS matching (n = 336,684), 81.5%,
17.5%, and 1.0% received either 1, 2, and ≥ 3 antidepres-
sant(s) with a benzodiazepine. Baseline characteristics
were well balanced after matching, as all variables had
an aSD < 0.1 (Table 1 and Additional file 5: Table S2).
AD+BZD therapy was associated with a moderately in-
creased risk of all-cause mortality (adjusted HR, 1.04;
95% CI, 1.02 to 1.06) and all-cause hospitalization (ad-
justed HR, 1.05; 95% CI, 1.04 to 1.06) when compared to
AD monotherapy; the top 20 frequent causes of
hospitalization are shown in Additional file 6: Table S3.
In contrast, the risk of suicide attempt/self-harm was
significant increased with AD+BZD therapy (adjusted
HR, 1.73; 95% CI, 1.15 to 2.61) as compared with AD
monotherapy (Figs. 2 and 3).
Significant effect modifications were found when strati-
fied for age and sex (p for interaction < 0.0001), as the risk
of all-cause mortality was increased among males for AD+
BZD therapy (adjusted HR, 1.11; 95% CI, 1.08 to 1.15) but
moderately reduced among females (adjusted HR, 0.97;
95% CI, 0.93 to 0.998). Moreover, age-stratified analyses
showed that among those aged < 65 years, AD+BZD
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Table 1 Baseline characteristics of study subjects after propensity score matching, where values are percentages unless stated
otherwise
Propensity score-matched cohort (1:1 match)
N = 519,780 (%)
AD monotherapy AD + BZD therapy aSD
N = 259,890 (%) N = 259,890 (%)
Follow-up (years; mean ± std) 5.56 ± 3.86 6.24 ± 4.15 0.169
Age (years; mean ± std) 43.9 ± 17.1 43.4 ± 16.1 0.027
Male 112,411 43.25 113,154 43.54 0.006
Type of insurance 0.000
Healthcare insurance 250,074 96.22 250,233 96.28
Medical aid 9595 3.69 9449 3.64
Residential district 0.000
Metropolitan 139,908 53.83 140,636 54.11
Urban 44,264 17.03 44,499 17.12
Rural 75,090 28.89 74,159 28.53
Income level 0.000
1st quartile 46,610 17.93 46,059 17.72
2nd quartile 51,464 19.80 51,229 19.71
3rd quartile 62,992 24.24 62,850 24.18
4th quartile 83,323 32.06 84,424 32.48
Charlson Comorbidity Index (mean ± std) 0.36 ± 0.78 0.35 ± 0.78 0.011
0 202,809 78.04 204,010 78.50
1 31,040 11.94 30,658 11.80
2 17,963 6.91 17,425 6.70
3 7541 2.90 7272 2.80
4 149 0.06 133 0.05
≥ 5 388 0.15 392 0.15
Comorbidities†
Anxiety 4618 1.78 4560 1.75 0.002
Cancer 3545 1.36 3468 1.33 0.003
Cerebrovascular disease 4558 1.75 4482 1.72 0.002
Chronic kidney disease 619 0.24 607 0.23 0.001
Chronic obstructive pulmonary disease 8930 3.44 8659 3.33 0.006
Dementia 1997 0.77 2012 0.77 0.001
Diabetes mellitus 15,116 5.82 14,741 5.67 0.006
Epilepsy 1071 0.41 1037 0.40 0.002
Fractures 1327 0.51 1299 0.50 0.002
Hypertension 27,875 10.73 26,808 10.32 0.013
Hyperlipidemia 26,392 10.16 25,583 9.84 0.010
Insomnia 7784 3.00 7547 2.90 0.005
Ischemic heart disease 1534 0.59 1496 0.58 0.002
Osteoarthritis 21,739 8.36 21,200 8.16 0.008
Parkinson’s disease 221 0.09 201 0.08 0.003
Rheumatoid arthritis 3656 1.41 3565 1.37 0.003
Substance abuse 944 0.36 1021 0.39 0.005
Jeong et al. BMC Medicine          (2020) 18:387 Page 5 of 11
therapy was associated with an increased risk of all-cause
mortality (adjusted HR, 1.33; 95% CI, 1.29 to 1.38), but
showed reduced risk in those aged ≥ 65 years (adjusted
HR, 0.91; 95% CI, 0.89 to 0.94). Among AD+BZD therapy
recipients, those who received short-acting BZDs showed
a slightly increased risk of mortality (adjusted HR, 1.07;
95% CI, 1.04 to 1.09), whereas those who received long-
acting BZDs showed a 7% reduced risk (adjusted HR, 0.93;
95% CI, 0.90 to 0.97). Finally, similarly increased risk of
mortality was observed in those who discontinued BZDs
Table 1 Baseline characteristics of study subjects after propensity score matching, where values are percentages unless stated
otherwise (Continued)
Propensity score-matched cohort (1:1 match)
N = 519,780 (%)
AD monotherapy AD + BZD therapy aSD
N = 259,890 (%) N = 259,890 (%)
History of medication use†
Angiotensin-converting-enzyme inhibitors 2036 0.78 1961 0.75 0.003
Angiotensin II receptor blockers 15,077 5.80 14,664 5.64 0.007
Anticholinergics 25,843 9.94 25,751 9.91 0.001
Antiplatelets and anticoagulants 19,241 7.40 18,730 7.21 0.008
Antipsychotics 1997 0.77 1926 0.74 0.003
Anticonvulsants 4345 1.67 4363 1.68 0.001
Digoxin 340 0.13 345 0.13 0.001
Non-insulin glucose-lowering agents 8765 3.37 8607 3.31 0.003
Anti-inflammatory analgesics 101,017 38.87 100,937 38.84 0.001
β-blockers 10,291 3.96 9616 3.70 0.014
Calcium channel blockers 16,733 6.44 16,063 6.18 0.011
Insulin 885 0.34 872 0.34 0.001
Lipid-lowering agents 14,689 5.65 14,207 5.47 0.008
Narcotic analgesics 62,273 23.96 61,439 23.64 0.008
Nonsteroidal anti-inflammatory drugs 139,850 53.51 139,982 53.84 0.001
Other anxiolytics 14,899 5.73 14,851 5.71 0.001
Thiazide diuretics 10,403 4.00 9949 3.83 0.009
AD antidepressant, aSD absolute standardized difference, BZD benzodiazepine, std standard deviation
†Assessed within the year before cohort entry
Fig. 2 Risk of all-cause mortality, suicide attempt/self-harm, and all-cause hospitalization for antidepressant monotherapy and
antidepressant+benzodiazepine concomitant therapy in the propensity score-matched cohort. Note: AD, antidepressant; BZD, benzodiazepine; CI,
confidence interval; IR, incidence rate; RD, risk difference. *Incidence rate = (number of events/total person-years) × 1000. †Adjusted for age, sex,
CCI, comorbidities, and concomitant medications
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(adjusted HR, 1.04; 95% CI, 1.01 to 1.06) and continued
BZDs (adjusted HR, 1.07; 95% CI, 1.02 to 1.11) (Fig. 4).
Results of sensitivity analyses remained largely consistent
with our main findings (Additional file 7: Fig. S4).
Discussion
Of 2.6 million patients diagnosed with depression in
South Korea between 2002 and 2017, this nationwide
cohort study found a moderate 4% increased risk of all-
cause mortality with AD+BZD therapy, as compared to
AD monotherapy, but a 74% increased risk of suicide at-
tempt/self-harm. Subgroup analyses revealed an elevated
risk of all-cause mortality associated with AD+BZD ther-
apy among males, those aged < 65 years, and those who
received short-acting BZDs with antidepressants. To our
knowledge, this large-scale observational study is the
Fig. 3 Kaplan-Meier survival curve of all-cause mortality, suicide attempt/self-harm, and all-cause hospitalization
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first study conducted using nationwide data to provide
real-world evidence that initiating BZDs with AD is as-
sociated with potentially fatal harms in the treatment of
depression.
No study to date has assessed the risk of mortality as-
sociated with AD+BZD therapy versus AD monotherapy
among adults with depression. However, one meta-
analysis of randomized trials that examined the associ-
ation between adverse events and AD+BZD therapy was
available for an indirect comparison. We assumed these
adverse events to have been severe, as their occurrence
resulted in patients dropping out of the trial. Compar-
able to our observed increased risk of mortality associ-
ated with AD+BZD therapy, this meta-analysis found
that the AD+BZD group was more likely to report ≥ 1
adverse events when compared to the AD monotherapy
group (pooled risk ratio, 1.12; 95% CI, 1.01–1.23) [8].
Based on our abovementioned assumption on adverse
events, they could serve as surrogate measures or pre-
cursors to either mortality or hospitalizations. Moreover,
Fig. 4 Forest plot summarizing the risk of all-cause mortality for antidepressant monotherapy and antidepressant+benzodiazepine concomitant
therapy after stratifying for age, sex, type of benzodiazepines, and benzodiazepine discontinuation. Note: AD, antidepressants; aSD, absolute
standardized difference; BZD, benzodiazepines. †Patients who received both short- and long-acting BZDs together with antidepressants on the
index date were not considered for in this subgroup analysis as they were unable for classification. ‡Sex-stratified analysis: all covariates remained
balanced among females as all aSD values were < 0.1, whereas males showed imbalance in health insurance type (aSD 0.152) and residential
district (aSD 0.143); age-stratified analysis: all covariates remained balanced among those < 65 years, while CCI (aSD 0.164) and history of NSAIDs
use (aSD 0.115) were imbalanced among those ≥ 65 years; stratified for BZD type: all covariates remained balanced among those who received
short-acting BZDs but showed imbalance in residential district (aSD 0.180) and CCI (aSD 0.147) among those who received long-acting BZDs;
stratified for discontinuation of BZD: all covariates remained balanced among those who discontinued BZDs, while age (aSD 0.169), health
insurance type (aSD 0.132), income level (aSD 0.120), and history of insomnia (aSD 0.107) showed imbalance among those who continued BZDs
at 6 months after the index date. P-for-interaction not estimated as subtype of BZDs was our exposure of interest
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several systematic reviews of observational studies and
randomized trials found BZD use to be positively associ-
ated with suicides [26, 27], accidents [28], or falls [29].
In addition to these events increasing the risk of death,
the risks of suicide attempts and mortality were also
higher among patients with depression and anxiety com-
pared to those with depression alone [26, 30]. Thus, re-
cipients of AD+BZD therapy in our study are likely to
be depressed patients exhibiting comorbid anxiety.
While administering BZDs may alleviate anxiety, it sim-
ultaneously puts these patients at higher risks of adverse
events (hospitalization or mortality). With no published
evidence available, to the best of our knowledge, for dir-
ect comparison, our findings in the meantime suggest
the potential need in revisiting the rationale behind co-
prescribing BZDs with ADs to treat depression, as this
clinical practice was associated with a moderately ele-
vated risk of mortality.
Our findings suggest that AD+BZD therapy should
be carefully used across all age groups, which are
supported by both our main and age-stratified ana-
lyses showing an increased risk of all-cause mortality.
Although we observed a statistically insignificant risk
of mortality associated with AD+BZD therapy among
patients ≥ 65 years of age, use of AD+BZD therapy is
not warranted in the elderly as BZDs were previously
reported to have deleterious effects in this age group
[12, 13]. Thus, in addition to their rather well-known
harmful effects among the elderly, BZDs should also
be used with caution in young and middle-aged adults
with incident depression. In the meantime, healthcare
providers should consider ways to minimize the use
of AD+BZD therapy as the harms appear to outweigh
its benefits in treating adults with incident depression
across all age groups.
Our study showed that 54.9% (before PS matching) of
adults with incident depression received AD+BZD ther-
apy, which was comparable to those (40–50%) in previ-
ous studies on other Asian [31, 32] or Caucasian
populations [33]. While the clinical manifestation of de-
pression in Korean patients could have been different
from that of patients of other countries, cultures, or eth-
nicities [34], we found similar proportions of AD+BZD
use among patients with depression. Moreover, 12% of
AD+BZD recipients (n = 31,316) in our study continued
BZDs at 6 months after follow-up. Despite this observa-
tion not agreeing with current guidelines that recom-
mend BZD use to not exceed 4 weeks [35], we believe
that the prolonged use of BZDs may have been due to
either its own dependence or because concomitant use
of BZDs with ADs in treating incident depression may
have partially contributed to dependence [36].
This study has several strengths. To the best of our
knowledge, this is the first study to have examined the
risk of mortality associated with two treatment options
commonly used to treat early-stage depression. Second,
we used a nationwide South Korean healthcare database,
highly representative of the entire South Korean popula-
tion, to identify 2.6 million adults with depression. As
NHIS-NHID provides data to external investigators after
rigorous internal review for data validity, it is considered
an extremely reliable data source. Third, misclassifica-
tion of study outcomes is unlikely to have occurred in
our study as all records of death in the NHIS-NHID
were linked with South Korea’s national vital statistics,
which are maintained by Statistics Korea [15]. Lastly, we
applied PS matching that included numerous covariates
to obtain comparability and balance between the two
treatment groups. We also applied two other methods of
PS that utilized all patients from our study cohort and
found a consistently elevated risk of mortality associated
with AD+BZD therapy.
Our study also has limitations. First, there may have
been exposure misclassification as recipients of con-
comitant therapy were classified based on prescriptions
made on the same day. However, we expect exposure
misclassification to be minimal in our study, as the sen-
sitivity analysis that varied the definition of concomitant
therapy showed consistent findings. Second, our main
findings, which used the intention-to-treat approach,
may have underestimated the risk of study outcomes, as
patients would have remained in the study regardless of
their treatment patterns throughout follow-up, which
may have led to an overestimation of person-time. How-
ever, the results of our sensitivity analysis that used the
as-treated approach (censored follow-up at treatment
discontinuation) were consistent. Third, despite account-
ing for various confounding factors and using three
different PS methods, residual confounding from un-
measured or unaccounted confounders may still be
present. However, residual confounding from unmeas-
ured confounders is likely to be small as our HR esti-
mate for mortality was close to the null, which is also
supported from the estimated E-value that suggests that
an unmeasured confounder has to be associated with
both the exposure and outcome by greater than 1.24-
fold in order to affect the observed association (Add-
itional file 8: Table S4). We therefore suggest that future
studies should consider clinical features, for instance,
the main symptoms, severity of depression, and suicidal
ideation, factors that could not be measured in this
study due to structural limitations, possibly by using
linked data between health insurance claims and elec-
tronic medical records of hospitals and clinics. This
would then be able to provide better understanding on
the observed protective effects of AD+BZD therapy on
mortality risks among those aged ≥ 65 years, females, or
those who received long-acting BZDs.
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Conclusions
In conclusion, the addition of BZD to AD monotherapy
to treat depression was associated with a moderately in-
creased risk of all-cause mortality when compared to
AD monotherapy. This may be due to the risks associ-
ated with BZDs; therefore, careful consideration is war-
ranted when deciding to concomitantly initiate BZDs
with ADs. While further studies accompanied with more
detailed clinical data could provide insight into the
underlying effect modifications by gender or age, our
findings suggest healthcare providers to exercise caution
in co-prescribing BZDs and ADs to treat patients with
depression, weighing the risk-benefits associated with
concomitant AD+BZD therapy over AD monotherapy.
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